© EdiMembre/MerckAlternative ProteinMerck and mantro enter the foodtech marketThe laboratory division of Merck KGaA has, in partnership with the German company builder Mantro GmbH, established EdiMembre Inc, a Massachusetts-based company set to deploy Merck’s technologies for … more ➔
adobe stock photos - Tomas RaginaPharmaceutical SupplyTrump delays 250% tariffs on non-U.S. pharmaceuticalsU.S. President Donald Trump’s announcement regarding new tariffs on pharmaceutical goods imported into the United States has been delayed. Despite the President’s threat early last week that a tariff … more ➔
NanoCell Therapeutics IncFinancingCPTx and NanoCell Therapeutics secure Eurostars grant to develop non-viral in-vivo CAR-T therapiesGerman CPTx GmbH, its CDMO Gxstrands, and the US start-up NanoCell Therapeutics have been awarded a Eurostars grant for their QUIET-CAR project, funded through the EU’s Horizon Europe programme and … more ➔
Pilatus BiosciencesCancer ImmunotherapyPilatus Biosciences Enters Clinical Collaboration with RochePilatus Biosciences AG, a Swiss biotechnology company headquartered in Epalinges with operations in the United States and South Korea, has entered into a clinical trial collaboration with Roche AG. As … more ➔
adpbe stock photos - David A Litman CancerBayer announces US$1.3bn oncology deal with Kumquat BiosciencesBayer AG’s Pharmaceuticals division in Berlin has expanded its oncology pipeline through a licensing and collaboration agreement with US-based Kumquat Biosciences Inc., which may yield up to US$1.3bn … more ➔
IO BiotechCancer vaccinationIO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approvalIO Biotech has published top-line results from its pivotal Phase 3 trial evaluating the therapeutic cancer vaccine IO102-IO103 (Cylembio) in combination with pembrolizumab in patients with advanced melanoma. … more ➔
lkov - adobe stock photoClinical trialsNovartis’ Ianalumab achieves Phase III endpoint in Sjögren’s syndromeNovartis AG has reported a clinical milestone in the treatment of Sjögren’s syndrome, with its BAFF receptor blocker Ianalumab (VAY736) becoming the first investigational therapy to demonstrate a … more ➔
Dewpoint Therapeutics IncRestructuringDewpoint Therapeutics cuts workforce, refocuses pipelineDewpoint Therapeutics Inc. has announced a significant corporate restructuring. Approximately 70% of its 130 employees will be laid off, and operations will be consolidated at the company’s Boston … more ➔
adobe stock photos - ndomble RegulatoryEU Biotech Act: Have your say!The European Commission has launched a public consultation to support the development of the European Biotech Act, which is now being prioritised after a previous delay. The Commission plans to publish … more ➔
Ragon Institute/MITHIVReiThera starts study on HIV vaccineItalian biotech company ReiThera srl has commenced safety trials of its experimental HIV vaccine candidate, GRAdHIVNE1, in Harare, Zimbabwe. Developed in partnership with the Ragon Institute at Harvard … more ➔
© EdiMembre/Merck
adobe stock photos - Tomas Ragina
NanoCell Therapeutics Inc
Pilatus Biosciences
adpbe stock photos - David A Litman 
IO Biotech
lkov - adobe stock photo
Dewpoint Therapeutics Inc
adobe stock photos - ndomble 
Ragon Institute/MIT